Captain Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship with Trough FEV1

被引：0
|
作者：
Fowler, A. [1 ]
Kerstjens, H. [2 ,3 ]
Bailes, Z. [1 ]
Tabberer, M. [1 ]
Barnes, N. [4 ,5 ,6 ,7 ]
Peachey, G. [1 ]
Oppenheimer, J. [8 ]
Lee, L. [9 ]
机构：
[1] GSK, Stockley Pk West, Uxbridge, Middx, England
[2] Univ Groningen, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] GSK, Brentford, England
[5] Barts & London Queen Marys Sch Med & Dent, Brentford, England
[6] GSK, London, England
[7] Barts & London Queen Marys Sch Med & Dent, London, England
[8] Rutgers New Jersey Med Sch, Newark, NJ USA
[9] GSK, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5626
引用
收藏
页数：2
相关论文
共 22 条
  • [1] Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
    Pavord, Ian
    Peachey, Guy
    Kerstjens, Huib
    Kerwin, Edward
    Nathan, Robert
    Hanania, Nicola
    Pascoe, Steven
    Fowler, Andrew
    Bailes, Zelie
    Edwards, Dawn
    Sule, Neal
    Barnes, Neil
    Boulet, Louis-Philippe
    Tabberer, Maggie
    Lee, Laurie
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB241 - AB241
  • [2] Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
    Pavord, Ian
    Peachey, Guy
    Kerstjens, Huib
    Kerwin, Edward
    Nathan, Robert
    Hanania, Nicola A.
    Pascoe, Steven
    Fowler, Andrew
    Bailes, Zelie
    Edwards, Dawn
    Sule, Neal
    Barnes, Neil
    Boulet, Louis-Philippe
    Tabberer, Maggie
    Lee, Laurie A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (06) : 459 - 460
  • [3] Captain Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma
    Lee, L.
    Boulet, L.
    Fowler, A.
    Tabberer, M.
    Bailes, Z.
    Pascoe, S.
    Kerwin, E. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [4] Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study
    Nakamura, Yoichi
    Hozawa, Soichiro
    Sagara, Hironori
    Ohbayashi, Hiroyuki
    Lee, Laurie A.
    Crawford, Jodie
    Tamaoki, Jun
    Nishi, Takanobu
    Fowler, Andrew
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1657 - 1665
  • [5] Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial
    Lee, Laurie A.
    Bailes, Zelie
    Barnes, Neil
    Boulet, Louis-Philippe
    Edwards, Dawn
    Fowler, Andrew
    Hanania, Nicola A.
    Kerstjens, Huib A. M.
    Kerwin, Edward
    Nathan, Robert
    Oppenheimer, John
    Papi, Alberto
    Pascoe, Steven
    Brusselle, Guy
    Peachey, Guy
    Sule, Neal
    Tabberer, Maggie
    Pavord, Ian D.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (01): : 69 - 84
  • [6] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Sandeep Bansal
    Martin Anderson
    Antonio Anzueto
    Nicola Brown
    Chris Compton
    Thomas C. Corbridge
    David Erb
    Catherine Harvey
    Morrys C. Kaisermann
    Mitchell Kaye
    David A. Lipson
    Neil Martin
    Chang-Qing Zhu
    Alberto Papi
    npj Primary Care Respiratory Medicine, 31
  • [7] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Bansal, Sandeep
    Anderson, Martin
    Anzueto, Antonio
    Brown, Nicola
    Compton, Chris
    Corbridge, Thomas C.
    Erb, David
    Harvey, Catherine
    Kaisermann, Morrys C.
    Kaye, Mitchell
    Lipson, David A.
    Martin, Neil
    Zhu, Chang-Qing
    Papi, Alberto
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2021, 31 (01)
  • [8] An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
    Wells, J. M.
    Bhatt, S. P.
    Carr, T. F.
    Criner, G. J.
    Halpin, D. M. G.
    Han, M. K.
    Jain, R.
    Kaye, M. G.
    Kraft, M.
    Lipson, D. A.
    Mapel, D.
    Mammen, M. J.
    McEvoy, C.
    Midwinter, D.
    Singh, D.
    Wise, R.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [9] Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
    Mannino, David
    Bogart, Michael
    Germain, Guillaume
    Huang, Shirley P.
    Ismaila, Afisi S.
    Laliberte, Francois
    Jung, Young
    MacKnight, Sean D.
    Stiegler, Marjorie A.
    Duh, Mei Sheng
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 491 - 504
  • [10] Efficacy And Safety Of Once-Daily Fluticasone Furoate/vilanterol (ff/vi) And Ff Over 12 Weeks In Patients With Persistent Asthma
    Bernstein, D. I.
    Bateman, E. D.
    Woodcock, A.
    Toler, W. T.
    Forth, R.
    Jacques, L.
    Nunn, C.
    O'Byrne, P. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
123